Citigroup Has Lowered Expectations for ArriVent BioPharma (NASDAQ:AVBP) Stock Price

Key Points

• Citigroup cut ArriVent BioPharma’s price target from $40 to $20 while maintaining a “buy” rating, implying roughly 18% upside from the reported $16.89 share price.
• Several analysts also reduced their targets, although the stock retains a “Moderate Buy” consensus rating from 11 analysts with an average target of $29.67.
• The company’s Phase 3 FURVENT trial for lead drug candidate firmonertinib failed to meet its primary endpoint, triggering an approximately 58%–60% share-price decline and weakening the near-term investment outlook.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) had its price objective reduced by stock analysts at Citigroup from $40.00 to $20.00 in a report released on Wednesday, Benzinga reports. The firm presently has a "buy" rating on the stock. Citigroup's target price would suggest a potential upside of 18.45% from the stock's current price.

AVBP has been the subject of a number of other reports. Truist Financial lowered their price target on shares of ArriVent BioPharma from $45.00 to $18.00 and set a "buy" rating for the company in a report on Tuesday. JonesTrading decreased their price objective on shares of ArriVent BioPharma from $45.00 to $22.00 and set a "buy" rating on the stock in a research report on Wednesday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of ArriVent BioPharma in a research note on Friday, July 17th. HC Wainwright raised their target price on ArriVent BioPharma from $44.00 to $47.00 and gave the stock a "buy" rating in a research note on Monday, August 17th. Finally, BTIG Research reduced their price target on ArriVent BioPharma from $42.00 to $29.00 and set a "buy" rating on the stock in a report on Wednesday. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $29.67.

ArriVent BioPharma Stock Performance

AVBP traded up $1.79 on Wednesday, hitting $16.89. 2,923,780 shares of the company were exchanged, compared to its average volume of 638,054. The firm has a fifty day simple moving average of $29.57 and a two-hundred day simple moving average of $29.43. The stock has a market capitalization of $832.57 million, a PE ratio of -4.68 and a beta of 1.34. ArriVent BioPharma has a 12 month low of $11.36 and a 12 month high of $35.83.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.06). On average, equities analysts expect that ArriVent BioPharma will post -4.11 earnings per share for the current year.

Institutional Investors Weigh In On ArriVent BioPharma

A number of large investors have recently modified their holdings of the stock. Quantbot Technologies LP purchased a new position in ArriVent BioPharma in the second quarter worth about $59,000. Bank of New York Mellon Corp grew its holdings in shares of ArriVent BioPharma by 3.2% during the first quarter. Bank of New York Mellon Corp now owns 75,448 shares of the company's stock valued at $1,741,000 after buying an additional 2,337 shares during the last quarter. Jupiter Topco LLC bought a new stake in shares of ArriVent BioPharma during the second quarter valued at approximately $226,000. Arizona State Retirement System purchased a new position in ArriVent BioPharma in the 2nd quarter worth approximately $233,000. Finally, Glenmede Trust Co. NA bought a new position in ArriVent BioPharma in the 1st quarter valued at approximately $209,000. Institutional investors own 9.48% of the company's stock.

ArriVent BioPharma News Summary

Here are the key news stories impacting ArriVent BioPharma this week:

• Neutral Sentiment: Trading in AVBP was temporarily halted pending news before the company released its clinical-trial update, reflecting the expected market sensitivity of the announcement.
• Negative Sentiment: ArriVent reported that the Phase 3 FURVENT trial of firmonertinib in previously untreated patients with EGFR exon 20 insertion-mutated non-small cell lung cancer failed to meet its primary endpoint of progression-free survival, as assessed by blinded independent central review. ArriVent FURVENT Phase 3 program update
• Negative Sentiment: The trial failure affects ArriVent’s lead asset and significantly weakens the near-term investment case. Analysts and industry coverage characterized the outcome as a late-stage setback, with the company reviewing its future plans for firmonertinib. ArriVent reviews firmonertinib plans
• Negative Sentiment: Reports described a roughly 58%–60% collapse in the stock following the failed primary endpoint, while the shares approached a new one-year low. The reaction reflects reduced expectations for firmonertinib’s approval and commercial potential. ArriVent shares plunge on FURVENT failure
• Negative Sentiment: Levi & Korsinsky announced a potential investor investigation after the trial failure. The notice highlighted shareholder losses and noted that ArriVent had launched a $250 million at-the-market stock offering approximately five months earlier, adding potential litigation and dilution concerns. ArriVent investor investigation notice

About ArriVent BioPharma

ArriVent BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing precision medicines for patients with genetically defined cancers. The company seeks to identify promising therapies developed in other regions and advance them through clinical development and regulatory approval in the United States and other markets.

ArriVent's lead product candidate is furmonertinib, an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor designed to target specific EGFR mutations in non-small cell lung cancer, including EGFR exon 20 insertion mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.